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Background: The treatment landscape for idiopathic pulmonary fibrosis, a devastating lung disease, is changing. To
investigate the effectiveness of treatments for idiopathic pulmonary fibrosis we undertook a systematic review,
network meta-analysis and indirect comparison.
Methods: We searched MEDLINE, EMBASE and The Cochrane library for relevant studies. Randomised controlled
trials of pirfenidone, nintedanib or N-acetylcysteine were eligible. Predefined processes for selecting references,
extracting data and assessing study quality were applied. Our network meta-analysis of published data used a fixed
effect model. For forced vital capacity measures a standardised mean difference approach was used and converted
to odds ratios for interpretation.
Results: Of 1076 references, 67 were retrieved and 11 studies included. Studies were of reasonable size, populations
were similar, and the overall quality was good. Only two treatments, pirfenidone (odds ratio 0.62, 95% credible
interval 0.52, 0.74) and nintedanib (0.41, 95% credible interval 0.34, 0.51) produced a statistically significant slowing
in the rate of forced vital capacity decline compared with placebo. In an indirect comparison, results indicate that
nintedanib is statistically significantly better than pirfenidone in slowing forced vital capacity decline (odds ratio
0.67, 95% credible interval 0.51, 0.88). Results were stable in scenario analysis and random effects models. Indirect
comparisons of mortality were not statistically significant between nintedanib and pirfenidone.
Conclusions: Two treatments show beneficial effects and when compared indirectly nintedanib appears to have
superior benefit on forced vital capacity. Limitations to indirect comparisons should be considered when
interpreting these results, however, our findings can be useful to inform treatment decisions.
Keywords: Idiopathic pulmonary fibrosis, Systematic review, Network meta-analysisBackground
The emergence of new evidence assessing the effective-
ness of therapies for idiopathic pulmonary fibrosis (IPF)
has created considerable interest and hope amongst pa-
tients, carers and clinicians. IPF is a devastating lung
disease characterised by the deposition of excessive scar
tissue within the lungs, which leads to breathlessness
and ultimately respiratory failure and death. It has been
well documented that the incidence of IPF is increasing
but the reasons for this are unclear. High mortality rates
are also well reported, and based on reported 5-year sur-
vival rates these would place IPF seventh on a list of fatal* Correspondence: Emma.Loveman@EffectiveEvidence.org
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unless otherwise stated.malignancies [1,2]. Until recently few treatment options
have been available, so the focus of treatment for many
patients has been symptom control and palliation [3].
The new optimism has stemmed from the fact pirfeni-
done, licensed in Europe in 2011 on the basis of evi-
dence from 4 randomised controlled trials (RCTs) [4-6],
has been shown in a recent multicentre RCT to slow the
rate of progression of IPF [7]. Furthermore another
agent (nintedanib) also met its primary end-point of redu-
cing the annual rate of pulmonary function decline in two
concurrent RCTs [8]. On the strength of these data the
Food and Drug Administration (FDA) and the European
Medicine Agency have recently approved both drugs for
use in IPF. These treatments have the potential for offer-
ing new hope for patients and carers [9] and clinicians will
be eager to offer patients the most appropriate treatment.al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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evidence for each of these treatments.
The purpose of this study was to systematically review
the clinical effectiveness of treatments for IPF and
present the findings of a network meta-analysis (NMA)
of key outcomes. We followed the principles of the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) Statement [10].
Methods
The methods for this systematic review are described in
a research protocol which is registered with the Inter-
national Prospective Register of Systematic Reviews [11].
This is an update of a previous systematic review which
also considered cost-effectiveness [12]. We identified ar-
ticles by searches of MEDLINE, EMBASE and the
Cochrane Library from database inception until May
2014 (for search strategies see Additional file 1: Table
S1). No language restrictions were applied. Two inde-
pendent reviewers screened titles and abstracts for inclu-
sion and full text articles were retrieved for further
scrutiny. These were reviewed by one reviewer and
checked by a second to identify RCTs that included par-
ticipants with a confirmed diagnosis of IPF. Eligible in-
terventions were N-acetylcysteine (NAC) alone or in
combination, pirfenidone or nintedanib, assessed on out-
comes measuring indices of lung function/capacity, exer-
cise performance, quality of life and adverse events.
Data extracted from studies included participant and
study characteristics, intervention and comparator de-
tails and results. An assessment of the methodological
quality of each included study was made [13]. Only pub-
lished data were included. One reviewer undertook data
extraction and quality assessment. These were checked
by a second reviewer and differences in opinion were re-
solved through discussion with a third reviewer. We syn-
thesised data in a narrative review and a Bayesian NMA
[14,15]. In circumstances where randomised evidence
between all relevant comparators is unavailable, network
meta-analysis combines evidence from trials comparing
different sets of treatments that form a connected evi-
dence network through common comparators, in this
case placebo. It retains within trial randomisation, allow-
ing direct and indirect evidence to inform estimates of
relative treatment effect in a single analysis. A vague
prior distribution (a normal distribution with mean zero
and variance 10,000) that contains little information
relative to the likelihood was used to ensure that results
were based on the data and not the choice of prior [16].
The NMA assessed five endpoints from 11 studies. An
advantage of NMA is that where interventions have not
been directly compared in RCTs the results of different
trials may be used to estimate the relative treatment effect
between two treatments through indirect comparison. Inaddition, the analysis allows for meta-regression to control
for study level covariates which may be a source of hetero-
geneity between trials [17].
The decline in FVC may be measured in two ways: as
a decline in FVC % predicted; and as an absolute change
from baseline (litres). In addition, some trials report vital
capacity, which can be assumed to be the same as FVC in
IPF. We used the standardised mean difference (SMD) ap-
proach to convert these measurements to a common scale
using Hedges’ adjusted g method to overcome potential
small sample bias [18]. The SMDs were then converted to
log odds ratios (logOR) using the method of Chinn [19] to
facilitate interpretation.
Our base case used the FVC % predicted where re-
ported, as by definition this includes adjustment for age
and sex. We conducted sensitivity analyses using litres
to examine variation in results arising from the different
measurement scales, and controlling for baseline FVC
through meta-regression.
The NMA was performed in WinBUGS using code
adapted from Dias and colleagues [15], see Additional
file 1: Appendix. Two chains were run for 50,000 simu-
lations with a burn-in period of 20,000 and a thinning
interval of 2, giving a final sample size of 30,000. Trace,
Brooks-Gelman-Rubin, and density plots were examined
to establish model convergence [20]. Fixed and random
effects models were conducted with best model fit deter-
mined by the deviance information criterion [21].
Results
Searches yielded 1076 unique references and 67 of these
were retrieved after initial screening. Of these we in-
cluded 11 studies (Figure 1). Five RCTs evaluated the
use of pirfenidone [4-7], three NAC [22-24], and three
nintedanib. [8,25] Two of the NAC studies [22,23] are in
fact one three arm RCT and as such there is not
complete independence in the placebo arms. Table 1
provides summary descriptions of each study. The par-
ticipants in all studies would likely be classed as mild to
moderate IPF, with baseline FVC [26] ranging from ap-
proximately 68% to 89% of predicted values. Participants
were around 64–68 years old, and were predominantly
men. In most studies diagnosis was within the previous
two years. The ratio of the forced expiratory volume in
the first second to the FVC was not reported consist-
ently across the studies. In three recent RCTs of pirfeni-
done [7] and nintedanib [7,8] this was required to be at
least 0.80 and at least 0.70 for study inclusion respect-
ively. For the RCT of NAC [22,23] this was required to
be at least 0.65. Although there were subtle differences
in trial inclusion criteria and diagnostic criteria, baseline
characteristics were broadly similar and are deemed to
be generally reflective of IPF patients with mild-to-
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Figure 1 PRISMA flow-chart of included studies.
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combined in meta-analysis. Primary outcomes were
based on the FVC in all but one trial [6]. With one ex-
ception [24], the studies had reasonable sample sizes
and were adequately powered to test differences in their
primary outcomes. Treatment duration ranged between
eight and 16 months, with the majority following up
until approximately 12 months.
Overall the studies were assessed as having a low or
uncertain risk of bias based on the assessment of ad-
equacy of concealment of allocations prior to assignment
to groups. All but one trial [24] were assessed as having
adequate randomisation procedures, and blinding was at
an unclear or low risk of bias in all but one trial [24].
Most trials described using an intention to treat (ITT)
analysis, although not all reported details. Several trials
presented adjusted analyses incorporating a range of
covariates and interactions [4,5,7,8,22,23]. As the adjust-
ments in the analyses were to take account of within-
study variability in the outcome associated with the
covariates, it did not negate meta-analysis of studies with
and without adjustment.
FVC
FVC outcome data used in the NMA can be seen in
Table 2 and the evidence network in Figure 2. Trials
were relatively homogeneous which validates the use of
fixed effect models. When combining the different FVC
treatment effects only pirfenidone and nintedanib pro-
duce a statistically significant slowing in the rate of FVC
decline compared with placebo (ORs < 1 with 95% credibleintervals [Crl] all less than 1) (Figure 3). These two treat-
ments were compared indirectly using the placebo as the
common comparator, and results indicate that nintedanib
is statistically significantly better than pirfenidone in slow-
ing FVC decline (OR 0.67, 95% CrI 0.51, 0.88). Random
effects analysis of FVC supports the trends seen although
the results were not statistically significant. Sensitivity ana-
lysis controlling for baseline FVC had little impact on re-
sults. Using FVC decline in litres, where reported, also
gave similar results.
A number of trials reported FVC as a dichotomous
outcome, using the proportion with a decline in FVC %
predicted of 10% or more (see Table 2). In our NMA
both treatments are associated with statistically signifi-
cantly lower odds of a decline in FVC % predicted
of ≥10% compared to placebo. The indirect comparison
of nintedanib and pirfenidone indicates that pirfenidone
is associated with slightly lower odds of a decline in
FVC % predicted of ≥10% compared to nintedanib, but
that this is non-significant (OR 1.21, 95% CrI 0.86, 1.72),
Additional file 1: Figure S1. Although not significant this
trend is divergent to the other FVC outcomes and may
be related to differences in definitions in the studies. For
example in one trial [7] this was the proportion with a
reduction >10% in FVC or death. It is also uncertain
whether studies reported this 10% decline as an absolute
or a relative decline. Three trials reported results as an
annualised decline in FVC but the network for this out-
come was not complete for comparison.
The FVC treatment effect versus placebo in one pirfe-
nidone trial [7] appears to be large when compared with
other trials. Two scenario analyses, first to exclude this
trial from the FVC % predicted model, and second to
adjust the numbers with an FVC decline greater than
10% to remove all cause deaths, did not substantively
alter the outputs of the NMA.Acute exacerbations
Evidence of acute exacerbations were reported in some of
the included trials but there were some differences in rates
reported. One trial [25] only reported the incidence per
100 years which we converted using the study sample size
to rate per year, and two trials [8] reported the proportion
of participants with at least one event (Additional file 1:
Table S2). Acute exacerbations are relatively rare occur-
rences and studies were not powered to detect a difference
in these rates, therefore results should be interpreted cau-
tiously (for the OR for acute exacerbation versus placebo,
see Additional file 1: Figure S2). Both nintedanib and pir-
fenidone have favourable point estimates, however only
the OR for nintedanib achieves significance. Owing to a
number of uncertainties with these data no indirect com-
parison was undertaken.
Table 1 Characteristics of randomised controlled trials included in the meta-analysis










Noble et al. 2011 [4] (Capacity 06) 171 (Pirfenidone 2403 mg/day) 72 67 72 ≤1 yr: 59% 74 Low
173 (Placebo)
Noble et al. 2011 [4] (Capacity 04) 174 (Pirfenidone 2403 mg/day) 72 66 71 ≤1 yr: 48% 75 Low
174 (Placebo)
Taniguchi et al. 2010 [5] 108 (Pirfenidone 1800 mg/day) 52 65 78 <1 yr: 37% 78 Unclear
104 (Placebo)
Azuma et al. 2005 [6] 73 (Pirfenidone 1800 mg/day) 39 64 90 <1 yr: 22% 80 Unclear
36 (Placebo)
King et al. 2014 [7] (Ascend) 278 (Pirfenidone 2403 mg/day) 52 68 78 1.7 68 Low
277 (Placebo)
Richeldi et al. 2011 [25] 85 (Nintedanib 300 mg/day) 52 65 75 1.2 80 Low
85 (Placebo)
Richeldi et al. 2014 [8] (INPULSIS-1) 309 (Nintedanib 300 mg/day) 52 67 81 1.7 80 Low
204 (Placebo)
Richeldi et al. 2014 [8] (INPULSIS-2) 329 (Nintedanib 300 mg/day) 52 67 78 1.6 79 Low
219 (Placebo)
Homma et al. 2012 [24], 38 (Inhaled NAC) 48 68 76 3 89 Unclear
38 (Placebo)
Raghu et al. 2012 [22], (PANTHER) 77 (NAC triple therapy) 32 68 75 1.1 71 Low
78 (Placebo)
IPFCRN, 2014 [23] (PANTHER) 133 (NAC) 60 68 78 1.1 73 Low
131 (Placebo)
aRisk of selection bias.
Loveman et al. BMC Pulmonary Medicine  (2015) 15:37 Page 4 of 7Mortality
All-cause mortality and respiratory-related mortality
were reported in trials of all treatments with the excep-
tion of inhaled NAC (Additional file 1: Table S3). The
NMA ORs for all-cause mortality compared with pla-
cebo showed that both nintedanib and pirfenidone had
favourable point estimates, however, only pirfenidone
was statistically significant (Additional file 1: Figure
S3). In indirect comparison pirfenidone is associated
with lower odds of all-cause mortality compared to nin-
tedanib, but this is not significant (OR 1.39, 95% CrI
0.70, 2.82). Similar results were seen for respiratory
mortality, see Additional file 1: Table S4 and Figure S4.
Studies were not powered to detect a difference on
mortality and therefore the results should be consid-
ered cautiously.
Other outcomes
The included trials reported other outcomes less consist-
ently and are therefore not appropriate for meta-
analysis. No studies that reported it showed significant
effects of treatment on diffusing capacity of the lung
[4-6,22,23], and effects on the six-minute walk test weremixed across the trials with only three showing a posi-
tive effect [4,7,22]. Few studies reported dyspnoea and
results were not significant [4,22,23]. On the St George’s
Respiratory Questionnaire, a measure of quality of life,
there were mixed results but overall it would appear that
the treatments have little effect on quality of life.
Discussion
This study presents a comprehensive review of evidence
of the effectiveness of three treatments for IPF and is a
timely addition to the ongoing appraisal of recently pub-
lished trials by patients and clinicians. Evidence for FVC
shows a significantly slower decline in patients treated
with pirfenidone or nintedanib compared to placebo.
When compared indirectly, there was a slower decline in
FVC for those treated with nintedanib than for pirfeni-
done. On endpoints thought more important for pa-
tients, such as mortality and acute exacerbations, there
were mixed results. Nintedanib was significantly better
than placebo for acute exacerbations and pirfenidone
was significantly better than placebo for mortality and
respiratory mortality. Indirect comparisons of mortality
outcomes were not statistically significant.
Table 2 Forced vital capacity outcomes reported in the included trials
Change in percent predicted FVC (%) or absolute change from baseline
(L)




Treatment Placebo P value Treatment Placebo P value
No. of
participants
Mean (SD) No. of
participants
Mean (SD) No. (%) No. (%)
Pirfenidone
Noble et al. 2011 [4] (Capacity 006) % pred 171 −9.0 (19.6) 173 −9.6 (19.1) 0.501 39 (23) 46 (27) 0.440
Noble et al. 2011 [4] (Capacity 004) % pred 174 −8.0 (16.5) 174 −12.4 (18.5) 0.001 35 (20) 60 (35) 0.01
Taniguchi et al. 2010 [5] Litres 104 −0.09 (0.20) 103 −0.16 (0.20) 0.042
Azuma et al. 2005 [6] Litres 72 −0.03 (0.22) 35 −0.13 (0.19) 0.037 9 (13) 12 (36) 0.003
King et al. 2014 [7] (Ascend) Litres 278 −0.122 (0.4) 277 −0.262 (0.4) 0.001 46 (16.5) 88 (31.8) <0.00001
Nintedanib
Richeldi et al. 2011 [25] % pred 85 −1.04 (9.1) 85 −6.0 (9.4) <0.001 20 (23.8) 37 (44.0) 0.004
Litres 85 −0.06 (0.37) 85 −0.23 (0.37) 0.001
Richeldi et al. 2014 [8] (INPULSIS-1) % pred 307 −2.8 (6.2) 204 −6.0 (6.2) <0.001 91 (29.5)c 88 (43.1) <0.001
Litres 307 −0.095 (0.22) 204 −0.205 (0.22) <0.001
Richeldi et al. 2014 [8] (INPULSIS-2) % pred 327 −3.1 (6.99) 217 −6.2 (6.99) <0.001 100 (30.4)e 79 (36.1)e 0.18
Litres 327 −0.095 (0.23) 217 −0.205 (0.23) <0.001
Inhaled NAC
Homma et al. 2012 [24], Litres 38 −0.09 (0.3) 38 −0.15 (0.2) 0.27
NAC triple therapy
Raghu et al. 2012 [22], (PANTHER) Litres 77 −0.24 (0.4) 78 −0.23 (0.4) 0.85
NAC
IPFCRN, 2014 [23] (PANTHER) % Pred d 133 −4.37 (7.5) 131 −4.76 (7.3) 0.67
Litres d 133 −0.18 (0.3) 131 −0.19 (0.3) 0.77
In some trials the vital capacity was reported which has been assumed to translate to the FVC.
Where not reported in individual trials measures of variance have been estimated from p-values reported using standard methodology.
aNumber of participants with a reduction in mean FVC of >10% (or 200 ml where applicable). bNumber of participants with a reduction in mean FVC of >10% or
death in ASCEND trial [7]. cBased on 309 patients in Nintedanib group. dFrom longitudinal analysis which adjusts for treatment time, interaction between time and
treatment, age, sex, race and height; assumes that data were missing at random and no data were imputed. eBased on 329 patients in Nintedanib group and 219
patients in placebo group.
Figure 2 Evidence network for forced vital capacity endpoint. Numbers on arrows refer to number of studies informing the comparison.
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Figure 3 Results of the network meta-analysis for forced vital capacity.
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should be taken into account when interpreting the find-
ings. The study is limited by inconsistent reporting of
the key outcomes in the trial publications and definitions
of outcomes differed. It has been questioned whether
the participants in one RCT (ASCEND) [7] differ from
other trials [9]. Although our assessment of heterogen-
eity suggests no statistically significant heterogeneity, the
rate of decline in FVC in the placebo group appears to
tail off near to the end of the trial. On observation of
placebo arms of all other included trials this is at a
greater rate, although the slope of decline seen in the
more recently published trials are more similar. One
possible reason for this reduction may be related to the
effects of the imputation of FVC data for patients who
died, however, in scenario analyses to test the consistency
of results we would suggest that the difference between
groups is similar to the other pirfenidone trials. Finally,
four of the trials did not report ITTanalysis, which is often
recommended as the least biased way to estimate inter-
vention effects in RCTs [27]. It is possible therefore that
treatment effects may be exaggerated in these trials
[5,6,8,24].
On FVC, within individual trials, results have not been
entirely consistent in their comparisons with placebo.
However, through NMA results show statistically signifi-
cant effects for both of pirfenidone and nintedanib. Both
treatments have received authorisation from the FDA
and in Europe. It is anticipated that the findings of our
indirect comparisons between nintedanib and pirfeni-
done will be of use to inform decision making in the
clinical setting. This is particularly important given that
until recently there has been an unmet need. Few trials
reported estimates of quality of life and good qualityresearch to establish the quality of life of patients with
IPF should be a priority. This would allow a fuller as-
sessment of the effectiveness of these treatments. Add-
itionally, these treatments do not stabilize or reverse the
decline in IPF and more research into treatments with
the potential to meet this aim is required.
Our review and NMA has been undertaken following
recognised principles for undertaking a systematic re-
view to ensure that our analyses are transparent and as
unbiased as possible. Additionally we ensured that only
the highest quality studies were included to limit uncer-
tainty in the results. Our group has no direct vested
interest in the pivotal trials. Limitations to our study are
that the NMA for FVC assumes the different measures
of FVC are equivalent and we converted results to odds
ratios to provide meaningful results. Although recog-
nised methodologies were used, these factors should be
considered when interpreting the results. Assumptions
of homogeneity, similarity, and consistency between dir-
ect and indirect evidence in our NMA were made [28],
however, uncertainties remain. For example, there could
be other sources of observed or unobserved heterogen-
eity which could impact on relative treatment effects.
Conclusions
Beneficial treatment effects were demonstrated across key
outcomes for two included interventions. In indirect com-
parison nintedanib was associated with significantly better
outcome on slowing the decline in FVC than pirfenidone
and this finding was robust in sensitivity analyses. Mortal-
ity rates showed trends in favour of pirfenidone but these
were not statistically significant. Our findings can be used
to help inform treatment decisions for this population of
patients who following the recent regulator’s approvals
will benefit from greater access to these therapies.
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Abbreviations
CrI: Credible interval; FVC: Forced vital capacity; IPF: Idiopathic pulmonary
fibrosis; ITT: Intent-To-Treat; NAC: N-acetylcysteine; NMA: Network meta-
analysis; OR: Odds ratio; RCT: Randomised controlled trial; SD: Standard
deviation; SMD: Standardised mean difference; VC: Vital capacity.
Competing interests
All authors declare no financial support for the submitted work from anyone
other than their employer. KOR has been a member of advisory boards for
both Intermune and Boehringer Ingelheim and has received consultancy
fees and research travel grants from both companies for advisory board
work. All other authors have no relationships with commercial entities that
might have an interest in the submitted work.
Loveman et al. BMC Pulmonary Medicine  (2015) 15:37 Page 7 of 7Authors’ contributions
EL developed the research protocol, assisted in the development of the
search strategy, assessed studies for inclusion, extracted data from and
quality assessed included studies, synthesised evidence, drafted and edited
the final manuscript and is the guarantor for the study. VRC synthesised
evidence, developed the NMA model and undertook the NMA, drafted the
manuscript. DAS synthesised evidence, developed the NMA model and
undertook the NMA, drafted the manuscript. JLC contributed to the
development of the research protocol, assessed studies for inclusion,
extracted data from and quality assessed included studies, synthesised
evidence and drafted the manuscript. AJC contributed to developing the
research protocol, extracted data from and quality assessed included studies,
synthesised evidence, drafted the manuscript. KMAO drafted the manuscript
background, assisted with the interpretation of the evidence, drafted the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
This research was funded from internal funds from the Southampton Health
Technology Assessments Centre (SHTAC) at the University of Southampton,
UK. We are grateful to Karen Welch, Information Specialist, SHTAC, University
of Southampton, for generating and running the literature searches.
Author details
1Effective Evidence LLP/Southampton Health Technology Assessments
Centre (SHTAC), University of Southampton, 1st Floor Epsilon House,
Enterprise Road, Southampton SO16 7NS, UK. 2SHTAC, University of
Southampton, 1st Floor Epsilon House, Enterprise Road, Southampton SO16
7NS, UK. 3ICON Health Economics, Seacourt Tower, West Way, Oxford OX2
0JJ, UK. 4Mater Misericordiae University Hospital, Dublin, Ireland.
Received: 14 November 2014 Accepted: 7 April 2015
References
1. Kim DS, Collard HR, King Jr TE. Classification and natural history of the
idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006;3:285–92.
2. American Cancer Society. Cancer Facts and Figures 2010. 2010. 13-6-2014
3. Costabel U. Idiopathic pulmonary fibrosis: recent milestones in disease
management. Eur Respir Rev. 2012;21:140.
4. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D,
et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY):
two randomised trials. Lancet. 2011;377:1760–9.
5. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al.
Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821–9.
6. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind,
placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med. 2005;171:1040–7.
7. King Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg
MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic
pulmonary fibrosis. N Engl J Med. 2014;370:2083–92.
8. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al.
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J
Med. 2014;370:2071–82.
9. Hunninghake GM. A new hope for idiopathic pulmonary fibrosis. NEJM.
2014;370:2142–3.
10. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA group. Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). BMJ.
2009;339:b2535.
11. Loveman E, Colquitt JL, Copley V, Scott DA, Clegg A, Richeldi L, et al.
Treatments for idiopathic pulmonary fibrosis: an updated systematic review
and network meta-analysis. PROSPERO: International prospective register of
systematic reviews. 2014
12. Loveman E, Copley V, Colquitt JL, Scott D, Clegg A, Jones J, et al. The
clinical and cost effectiveness of treatments for idiopathic pulmonary
fibrosis: a systematic review and economic evaluation. Health Technol
Assess, 2015;19:20.
13. Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance
for undertaking reviews in health care, Third edition. York, UK: York
Publishing Services Ltd., CRD; 2009.
14. Caldwell D, Ades AE, Higgins JPT. Simultaneous comparison of multiple
treatments: combining direct and indirect evidence. BMJ. 2005;331:897–900.15. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision
making 2: a generalized linear modeling framework for pairwise and
network meta-analysis of randomized controlled trials. Med Decis Making.
2013;33:607–17.
16. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. How vague is
vague? A simulation study of the impact of the use of vague prior
distributions in MCMC using WinBUGS. Stat Med. 2005;24:2401–28.
17. Salanti G, Marinho V, Higgins JPT. A case study of multiple-treatments meta-
analysis demonstrates that covariates should be considered. J Clin Epidemiol.
2009;62:857–64.
18. Egger M, Davey Smith G, Altman DG. Systematic reviews in health care:
meta-analysis in context. 2nd ed. London: BMJ Books; 2001.
19. Chinn S. A simple method for converting an odds ratio to effect size for use
in meta-analysis. Stat Med. 2000;19:3127–31.
20. Brooks SP, Gelman A. General methods for monitoring convergence of
iterative simulations. J Comput Graph Stat. 1998;7:434–55.
21. Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of
model complexity and fit. J R Stat Soc Ser B. 2002;64:583–639.
22. Raghu G, Anstrom KJ, King J, Lasky JA, Martinez FJ. Prednisone, azathioprine,
and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968–77.
23. The Idiopathic Pulmonay Fibrosis Clinical Research Network. Randomized
trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med.
2014;370:2093–101.
24. Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, et al.
Efficacy of inhaled N-acetylcysteine monotherapy in patients with early
stage idiopathic pulmonary fibrosis. Respirology. 2012;17:467–77.
25. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al.
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N
Engl J Med. 2011;365:1079–87.
26. Nathan SD, Shlobin OA, Weir N, Ahmad S, Kaldjob JM, Battle E, et al. Long-term
Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium.
Chest. 2011;140:221–9.
27. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 [updated March 2011]. The Cochrane
Collaboration; 2011.
28. Mills EJ, Thorlund K, Ionnidis JPA. Demystifying trial networks and network
meta-analysis. BMJ. 2013;346:f2914.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
